Physician profile
Khuda D Khan
NPI 1619946159
$359,064.86
in general payments reported to CMS, 2019-2025
24 companies · $29K in 2025
The $29K reported for 2025 was more than what 94% of Hematology & Oncology providers received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $81K · 2020: $35K · 2021: $37K · 2022: $70K · 2023: $50K · 2024: $57K · 2025: $29K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $100K · Consulting Fee: $18K · Travel and Lodging: $13K · Food and Beverage: $5,572.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $99,740.00 |
| Consulting Fee | $17,980.00 |
| Travel and Lodging | $12,891.16 |
| Food and Beverage | $5,571.67 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alexion Pharmaceuticals, INC. | $123,744.80 | 2019-2025 | Ultomiris |
| Genentech USA, INC. | $111,740.36 | 2019-2024 | Lunsumio, Polivy, Venclexta |
| Janssen Biotech, INC. | $68,099.74 | 2019-2023 | Tecvayli, Darzalex |
| Novartis Pharmaceuticals Corporation | $29,803.64 | 2019-2021 | |
| Genzyme Corporation | $15,140.46 | 2022-2025 | |
| Eisai INC. | $8,410.99 | 2020-2024 | |
| Abbott Laboratories | $861.07 | 2020-2025 | Diamondback Coronary, Coroflow |
| Astrazeneca Pharmaceuticals Lp | $223.79 | 2020-2024 | Wainua |
| Pfizer INC. | $148.33 | 2019-2021 | |
| Beone Medicines USA, INC. | $124.74 | 2025 | Brukinsa |
| Geron Corporation | $119.70 | 2025 | Rytelo |
| Merck Sharp & Dohme LLC | $119.00 | 2019-2021 | |
| Abbvie INC. | $108.50 | 2019-2024 | |
| Janssen Pharmaceuticals, INC | $100.39 | 2019 | |
| Astellas Pharma US INC | $88.46 | 2023-2025 | Xospata, Xtandi, Vyloy |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ipsen Biopharmaceuticals, INC | $87.68 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $34.99 | 2025 | Breyanzi |
| Amgen INC. | $27.62 | 2020-2021 | |
| Beigene USA, INC. | $25.09 | 2023 | Brukinsa |
| Celgene Corporation | $15.15 | 2019 | |
| Morphosys, US INC. | $14.87 | 2023 | Monjuvi |
| Teva Pharmaceuticals USA, INC. | $13.57 | 2019 | |
| Gilead Sciences, INC. | $11.92 | 2021 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Khuda Khan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.